EP4077377A4 - Anticorps bispécifiques comprenant des cystéines interchaînes mises en correspondance en alternance et leurs utilisations - Google Patents

Anticorps bispécifiques comprenant des cystéines interchaînes mises en correspondance en alternance et leurs utilisations Download PDF

Info

Publication number
EP4077377A4
EP4077377A4 EP20903525.2A EP20903525A EP4077377A4 EP 4077377 A4 EP4077377 A4 EP 4077377A4 EP 20903525 A EP20903525 A EP 20903525A EP 4077377 A4 EP4077377 A4 EP 4077377A4
Authority
EP
European Patent Office
Prior art keywords
alternating
bispecific antibodies
interchain cysteines
interchain
cysteines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20903525.2A
Other languages
German (de)
English (en)
Other versions
EP4077377A1 (fr
Inventor
Jack Chongyang LI
Minghan Wang
Hui Zou
Haiqun JIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phanes Therapeutics Inc
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of EP4077377A1 publication Critical patent/EP4077377A1/fr
Publication of EP4077377A4 publication Critical patent/EP4077377A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20903525.2A 2019-12-17 2020-12-03 Anticorps bispécifiques comprenant des cystéines interchaînes mises en correspondance en alternance et leurs utilisations Pending EP4077377A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962948953P 2019-12-17 2019-12-17
US201962952747P 2019-12-23 2019-12-23
US202062988144P 2020-03-11 2020-03-11
US202063007996P 2020-04-10 2020-04-10
US202062704973P 2020-06-05 2020-06-05
US202062706511P 2020-08-21 2020-08-21
PCT/US2020/063066 WO2021126538A1 (fr) 2019-12-17 2020-12-03 Anticorps bispécifiques comprenant des cyctéines interchaînes mises en correspondance en alternance et leurs utilisations

Publications (2)

Publication Number Publication Date
EP4077377A1 EP4077377A1 (fr) 2022-10-26
EP4077377A4 true EP4077377A4 (fr) 2024-07-03

Family

ID=76477869

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20903525.2A Pending EP4077377A4 (fr) 2019-12-17 2020-12-03 Anticorps bispécifiques comprenant des cystéines interchaînes mises en correspondance en alternance et leurs utilisations

Country Status (11)

Country Link
US (1) US20220411497A1 (fr)
EP (1) EP4077377A4 (fr)
JP (1) JP2023511652A (fr)
KR (1) KR20220113991A (fr)
CN (1) CN114929739A (fr)
AU (1) AU2020404817A1 (fr)
BR (1) BR112022010361A2 (fr)
CA (1) CA3160436A1 (fr)
IL (1) IL293868A (fr)
MX (1) MX2022007513A (fr)
WO (1) WO2021126538A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250009416A (ko) * 2022-03-11 2025-01-17 엘피사이언스 바이오파마, 엘티디. 변형된 항체 및 그의 용도
WO2024017371A1 (fr) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 Mutant favorisant l'appariement homologue de chaînes lourdes et légères d'un anticorps multispécifique
CN118837542A (zh) * 2023-04-24 2024-10-25 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
AU2024265570A1 (en) * 2023-04-29 2025-12-04 Innovent Biologics (Suzhou) Co., Ltd. Modified antibodies, antibody fragments thereof, and antibody-drug conjugates

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303354A1 (en) * 2012-12-03 2014-10-09 Novimmune S.A. Anti-CD47 Antibodies and Methods of Use Thereof
EP2915819A1 (fr) * 2012-11-05 2015-09-09 Zenyaku Kogyo Kabushikikaisha Procédé de production d'anticorps et de composition d'anticorps
US20190248899A1 (en) * 2016-05-26 2019-08-15 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2019177854A1 (fr) * 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anticorps anti-récepteur 1 aux folates et leurs utilisations
WO2019196522A1 (fr) * 2018-04-10 2019-10-17 广州爱思迈生物医药科技有限公司 Anticorps et procédé de modification d'anticorps
WO2019217145A1 (fr) * 2018-05-08 2019-11-14 Phanes Therapeutics, Inc. Anticorps anti-dll3 et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3286227A2 (fr) * 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Protéines multispécifiques de liaison à l'antigène
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
CN109963871A (zh) * 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
EP3658185A4 (fr) * 2017-07-28 2021-07-14 Phanes Therapeutics, Inc. Anticorps anti-tim-1 et leurs utilisations
US11401329B2 (en) * 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
JP7219265B2 (ja) * 2017-08-24 2023-02-07 フェインズ セラピューティクス，インコーポレーテッド 抗アペリン抗体及びその使用
CA3073733A1 (fr) * 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anticorps anti-lag-3 et leurs utilisations
WO2019173417A1 (fr) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anticorps anti-tip-1 et utilisations associées
BR112020016049A2 (pt) * 2018-03-09 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anti-cd73 e seus usos

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915819A1 (fr) * 2012-11-05 2015-09-09 Zenyaku Kogyo Kabushikikaisha Procédé de production d'anticorps et de composition d'anticorps
US20140303354A1 (en) * 2012-12-03 2014-10-09 Novimmune S.A. Anti-CD47 Antibodies and Methods of Use Thereof
US20180355065A1 (en) * 2012-12-03 2018-12-13 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
US20190248899A1 (en) * 2016-05-26 2019-08-15 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2019177854A1 (fr) * 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anticorps anti-récepteur 1 aux folates et leurs utilisations
WO2019196522A1 (fr) * 2018-04-10 2019-10-17 广州爱思迈生物医药科技有限公司 Anticorps et procédé de modification d'anticorps
WO2019217145A1 (fr) * 2018-05-08 2019-11-14 Phanes Therapeutics, Inc. Anticorps anti-dll3 et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021126538A1 *

Also Published As

Publication number Publication date
KR20220113991A (ko) 2022-08-17
CA3160436A1 (fr) 2021-06-24
JP2023511652A (ja) 2023-03-22
MX2022007513A (es) 2022-07-05
EP4077377A1 (fr) 2022-10-26
BR112022010361A2 (pt) 2022-08-16
WO2021126538A1 (fr) 2021-06-24
US20220411497A1 (en) 2022-12-29
NZ788321A (en) 2025-05-02
AU2020404817A1 (en) 2022-06-02
IL293868A (en) 2022-08-01
CN114929739A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3817769A4 (fr) Anticorps anti-cd47 humains et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3794037A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3762031A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3562508A4 (fr) Anticorps anti-lair1 et leurs utilisations
EP4034732A4 (fr) Ensemble de panneaux comprenant une rainure de flexion
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20240311BHEP

Ipc: C07K 16/28 20060101ALI20240311BHEP

Ipc: C07K 16/18 20060101AFI20240311BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240605

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20240530BHEP

Ipc: C07K 16/28 20060101ALI20240530BHEP

Ipc: C07K 16/18 20060101AFI20240530BHEP